StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$162.86−3.06 (-1.84%)

Close on Nov 18, 2026Market cap $16.55BP/E 23.9Yield –

Earnings

Neurocrine Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 10, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$1.10B
Non-GAAP diluted EPS, Q3 FY2026
$3.29
Latest guidance
Raised
Nov 2, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Neurocrine Biosciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 10, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 2, 2026after the close$1.10B–$1.96$3.29Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026after the close$959.00M+39.5%$1.39$2.85Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$814.50M+42.2%$1.91$1.94Release
Q4 FY2025ended Dec 31, 2025Feb 11, 2026after the close$805.50M+28.3%$1.48$1.88Release
Q3 FY2025ended Sep 30, 2025Oct 28, 2025after the close––––Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025after the close$687.50M+16.5%$1.06$1.65Release
Q1 FY2025ended Mar 31, 2025May 5, 2025after the close$572.60M+11.1%$0.08$0.70Release
Q4 FY2024ended Dec 31, 2024Feb 6, 2025after the close$627.70M+21.8%$1.00$1.69Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024before the open$622.10M+24.7%$1.24$1.81Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024before the open$590.20M+30.4%$0.63$1.63Release
Q1 FY2024ended Mar 31, 2024May 1, 2024before the open$515.30M+22.6%$0.42$1.20Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Neurocrine Biosciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
INGREZZA Net Product SalesFY2026$2.90B – $2.93B–NewNov 2, 2026
GAAP Amortization of Acquired Intangible AssetsGAAPFY2026$85.00M – $90.00M–LoweredNov 2, 2026
GAAP Amortization of Acquired Intangible AssetsGAAPFY2026$85.00M – $90.00M–LoweredJul 30, 2026
GAAP and Non-GAAP IPR&DFY2026$20.00M$20.00MReaffirmedMay 5, 2026
GAAP R&DGAAPFY2026$1.28B – $1.33B–NewNov 2, 2026
GAAP R&DGAAPFY2026$1.28B – $1.33B–LoweredJul 30, 2026
GAAP R&D ExpenseGAAPFY2026$1.20B – $1.25B$1.20B – $1.25BLoweredMay 5, 2026
GAAP SG&AGAAPFY2026$1.54B – $1.56B–RaisedNov 2, 2026
GAAP SG&AGAAPFY2026$1.58B – $1.60B–RaisedJul 30, 2026
GAAP SG&A ExpenseGAAPFY2026$1.38B – $1.40B$1.38B – $1.40BRaisedMay 5, 2026
IPR&DFY2026$34.00M–NewNov 2, 2026
IPR&DFY2026$23.00M–RaisedJul 30, 2026
Non-GAAP R&Dnon-GAAPFY2026$1.14B – $1.19B–NewNov 2, 2026
Non-GAAP R&Dnon-GAAPFY2026$1.14B – $1.19B–LoweredJul 30, 2026
Non-GAAP R&D Expensenon-GAAPFY2026$1.11B – $1.16B$1.11B – $1.16BLoweredMay 5, 2026
Non-GAAP SG&Anon-GAAPFY2026$1.29B – $1.31B–RaisedNov 2, 2026
Non-GAAP SG&Anon-GAAPFY2026$1.33B – $1.35B–RaisedJul 30, 2026
Non-GAAP SG&A Expensenon-GAAPFY2026$1.24B – $1.27B$1.24B – $1.27BRaisedMay 5, 2026

Guidance history

Every forecast Neurocrine Biosciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 2, 2026IPR&DFY2026$34.00MNew
Nov 2, 2026GAAP R&DFY2026$1.28B – $1.33BNew
Nov 2, 2026GAAP SG&AFY2026$1.54B – $1.56BRaised
Nov 2, 2026GAAP Amortization of Acquired Intangible AssetsFY2026$85.00M – $90.00MLowered
Nov 2, 2026Non-GAAP R&DFY2026$1.14B – $1.19BNew
Nov 2, 2026Non-GAAP SG&AFY2026$1.29B – $1.31BRaised
Nov 2, 2026INGREZZA Net Product SalesFY2026$2.90B – $2.93BNew
Jul 30, 2026GAAP R&DFY2026$1.28B – $1.33BLowered
Jul 30, 2026GAAP SG&AFY2026$1.58B – $1.60BRaised
Jul 30, 2026GAAP Amortization of Acquired Intangible AssetsFY2026$85.00M – $90.00MLowered
Jul 30, 2026Non-GAAP R&DFY2026$1.14B – $1.19BLowered
Jul 30, 2026Non-GAAP SG&AFY2026$1.33B – $1.35BRaised
Jul 30, 2026IPR&DFY2026$23.00MRaised
May 5, 2026GAAP and Non-GAAP IPR&DFY2026$20.00MReaffirmed
May 5, 2026GAAP R&D ExpenseFY2026$1.20B – $1.25BLowered
May 5, 2026GAAP SG&A ExpenseFY2026$1.38B – $1.40BRaised
May 5, 2026Non-GAAP R&D ExpenseFY2026$1.11B – $1.16BLowered
May 5, 2026Non-GAAP SG&A ExpenseFY2026$1.24B – $1.27BRaised
Feb 11, 2026GAAP and Non-GAAP IPR&DFY2026$20.00MNew
Feb 11, 2026GAAP R&D ExpenseFY2026$1.20B – $1.25BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Neurocrine Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Update
  10. Results
  11. Update
  12. News
  13. Results
  14. Update
  15. Update

See a number that looks wrong?